KOL Perspectives: Selective JAK inhibitors in IBD

KOL Perspectives: Selective JAK inhibitors in IBD

  • Products Id :- GDHC051SP
  • |
  • Pages: 26
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

KOL Perspectives: Selective JAK inhibitors in IBD


This KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Maintenance data for selective JAKs in Crohn's disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trials?Selective JAKs' expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs were broadly impressed with upadacitinib's Week 52 data in Crohn's disease, but views of filgotinib's Week 20 data were mixed

- Most KOLs stated that upadacitinib maintenance data matched and reinforced positive expectations for upadacitinib in Crohn's disease

- KOL consensus is that mid-range doses (6/12mg), or extended release equivalents should be used in upadacitinib's Phase III program.


- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during June 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "selective JAK inhibitors in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Executive Summary


Research Panel Composition

Results & Implications


Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com






Tofacitinib, upadacitinib, filgotinib, ozanimod, apremilast

select a license
Single User License
USD 2500 INR 171550
Site License
USD 5000 INR 343100
Corporate User License
USD 7500 INR 514650



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com